Abstract: The invention relates to 4-((6-oxopyrimidin-1(6H)-yl)methyl)benzoic acid, compositions thereof, and uses of either, for example in the treatment of ?1-antitrypsin deficiency (A1AD or AATD).

Abstract: The invention relates to specified carboxylic acid compounds of formula (1), and pharmaceutical compositions containing the compounds. The compounds may be inducers of ?1-antitrypsin (A1AT) and may be used in the treatment of a disease or disorder such as ?1-antitrypsin deficiency (A1AD or AATD).

Abstract: The invention relates to specified oxazole compounds of formula (1), and pharmaceutical compositions containing the compounds. The compounds may be inducers of ?1-antitrypsin (A1AT), and may be used in the treatment of a disease or disorder such as ?1-antitrypsin deficiency (A1AD or AATD).

Abstract: The invention relates to specified benzamide compounds of formula (1), and pharmaceutical compositions containing the compounds. The compounds may be inducers of ?1-antitrypsin (A1AT), and may be used in the treatment of a disease or disorder such as ?1-antitrypsin deficiency (A1AD or AATD).

Abstract: The invention relates to specified benzamide compounds of formula (1), and pharmaceutical compositions containing the compounds. The compounds may be inducers of ?1-antitrypsin (A1AT), and may be used in the treatment of a disease or disorder such as ?1-antitrypsin deficiency (A1AD or AATD).

Abstract: The invention relates to oxopyrimidinyl-methyl-benzamide derivatives, for example in a pharmaceutically acceptable salt form or crystal form, pharmaceutical compositions comprising the derivatives, and their medical use, in particular for use in the treatment of ?1-antitrypsin deficiency (A1AD or AATD).

Abstract: The invention relates to 4-((6-oxopyrimidin-1(6H)-yl)methyl)benzoic acid, compositions thereof, and uses of either, for example in the treatment of ?1-antitrypsin deficiency (A1AD or AATD).

Abstract: The invention relates to pharmaceutical compositions comprising (S)-1-(2-(trifluoromethyl)phenyl)sulfonyl)piperidine-3-carboxylic acid and their medical use, for example for use in the treatment of ?1-antitrypsin deficiency (AATD).

Abstract: The invention relates to specified benzamide compounds of formula (1), and pharmaceutical compositions containing the compounds. The compounds may be inducers of ?1-antitrypsin (A1AT), and may be used in the treatment of a disease or disorder such as ?1-antitrypsin deficiency (A1AD or AATD).

Abstract: The invention relates to specified benzamide compounds of formula (1), and pharmaceutical compositions containing the compounds. The compounds may be inducers of ?1-antitrypsin (A1AT), and may be used in the treatment of a disease or disorder such as ?1-antitrypsin deficiency (A1AD or AATD).

Abstract: The invention relates to specified benzamide compounds of formula (1), and pharmaceutical compositions containing the compounds. The compounds may be inducers of ?1-antitrypsin (A1AT), and may be used in the treatment of a disease or disorder such as ?1-antitrypsin deficiency (A1AD or AATD).

Abstract: The invention relates to specified carboxylic acid compounds of formula (1), and pharmaceutical compositions containing the compounds. The compounds may be inducers of ?1-antitrypsin (A1AT) and may be used in the treatment of a disease or disorder such as ?1-antitrypsin deficiency (A1AD or AATD).

Abstract: The invention relates to specified oxazole compounds of formula (1), and pharmaceutical compositions containing the compounds. The compounds may be inducers of ?1-antitrypsin (A1AT), and may be used in the treatment of a disease or disorder such as ?1-antitrypsin deficiency (A1AD or AATD).

Abstract: The invention relates to oxopyrimidinyl-methyl-benzamide derivatives, for example in a pharmaceutically acceptable salt form or crystal form, pharmaceutical compositions comprising the derivatives, and their medical use, in particular for use in the treatment of ?1-antitrypsin deficiency (A1AD or AATD).

Abstract: The invention relates to oxopyrimidinyl-methyl-benzamide derivatives, for example in a pharmaceutically acceptable salt form or crystal form, pharmaceutical compositions comprising the derivatives, and their medical use, in particular for use in the treatment of ?1-antitrypsin deficiency (A1AD or AATD).

Abstract: The invention relates to oxopyrimidinyl-methyl-benzamide derivatives, for example in a pharmaceutically acceptable salt form or crystal form, pharmaceutical compositions comprising the derivatives, and their medical use, in particular for use in the treatment of ?1-antitrypsin deficiency (A1AD or AATD).

Abstract: Compounds, pharmaceutical compositions of general formula (I) or (I?) or a pharmaceutically acceptable salt thereof, and methods for treating an inflammatory disorder: wherein: z is 1, 2 or 4; X is —CO—Yk—(R1)n; k is 0 or 1; Y is a cycloalkyl or polycycloalkyl, cycloalkenyl or polycycloalkenyl group; each R1 is a branched chain alkyl group; n is any integer from 1 to m, where m is the maximum number of substitutions permissible on the cyclo-group Y; and the compound comprises an amino lactam ring linked to an alkyl group —Yk—(R1)n by an amide group, wherein the carbon atom in the alkyl group at the 2-position relative to the carbon atom of the amide carbonyl is linked to each of the carbon atom of the amide carbonyl and three other carbon atoms by a single bond, and wherein the 2-position carbon atom has essentially tetrahedral bond angles.

Abstract: The invention provides compounds of general formulae (I)-(IV) or pharmaceutically acceptable salts thereof: The invention also provides methods of preparing the compounds, pharmaceutical compositions comprising the compounds and use of the compounds for the preparation of medicaments intended to modulate the activity of one or more members of the G-protein coupled receptor (GPCR) class. Compounds of the invention may be used to create a compound library for use in screening for agents which modulate signalling through GPCRs.

Abstract: Disclosed herein are methods of preventing or treating inflammatory diseases using sulfonamide analogs of 3-aminolactam compounds, each with aromatic “tail groups”. Compounds as defined by formulae (I) and (I?), and the medical uses of the compounds, are described herein.

Abstract: The invention provides compounds, compositions and uses of compounds of general formula (I) or pharmaceutically acceptable salts thereof, which are 3-aminocaprolactam derivatives, for the preparation of a medicament intended to treat an inflammatory disorder: wherein X is —CO—Y—(R1)n or SO2—Y—(R1)n; and Y is a cycloalkyl or polycycloalkyl group (such as an adamantyl, adamantanemethyl, bicyclooctyl, cyclohexyl, cyclopropyl group); or is a cycloalkenyl or polycycloalkenyl group.